WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient
How to treat CML patients who are resistant to inhibitors of BCR‐ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib‐treated CML in which intradermally administered WT1 peptide vaccine elicited WT1‐specific immune respo...
Gespeichert in:
| Veröffentlicht in: | European journal of haematology 2010-10, Vol.85 (4), p.358-360 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 360 |
|---|---|
| container_issue | 4 |
| container_start_page | 358 |
| container_title | European journal of haematology |
| container_volume | 85 |
| creator | Oji, Yusuke Oka, Yoshihiro Nishida, Sumiyuki Tsuboi, Akihiro Kawakami, Manabu Shirakata, Toshiaki Takahashi, Kazuko Murao, Ayako Nakajima, Hiroko Narita, Miwako Takahashi, Masuhiro Morita, Satoshi Sakamoto, Junichi Tanaka, Toshio Kawase, Ichiro Hosen, Naoki Sugiyama, Haruo |
| description | How to treat CML patients who are resistant to inhibitors of BCR‐ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib‐treated CML in which intradermally administered WT1 peptide vaccine elicited WT1‐specific immune responses and the resultant reduction in the persistent residual disease in co‐administration of Imatinib. BCR‐ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR‐ABL mRNA levels was associated with the increase in frequency of WT1‐specific cytotoxic T lymphocytes, notably effector‐memory type of that, in the patient’s peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure‐oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib. |
| doi_str_mv | 10.1111/j.1600-0609.2010.01497.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_755406120</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>755406120</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4347-60c36d19f1855091c2e9a0c5882b897c9b7c892b8681d9f0c0a335bbea242d373</originalsourceid><addsrcrecordid>eNqNkEtO5DAQhi0EopvHFUbesUpTfuThBQvUggHUiE0jlpZjVyS3knQmTqDZzRHmjHOScWhgPd5U6fdXZfkjhDJYsHguNwuWASSQgVpwiCkwqfLF7oDMvy8OyRwU8ERKyWbkJIQNAHDF8mMy45AJAZLNSfWyZrTDbvAO6aux1rdIfetGi4H2GOvgt21MaONb35g6hsG7MTbOBzRhoqlp6X1jhkiUf3__GXo0Azq6fFzRLqbYDmfkqDJ1wPPPekqeb2_Wy7tk9fTzfnm9SqwUMk8ysCJzTFWsSFNQzHJUBmxaFLwsVG5VmdtCxT4rmFMVWDBCpGWJhkvuRC5OycV-b9dvf40YBt34YLGuTYvbMeg8TSVkjEMkiz1p-20IPVa66-P_-nfNQE-S9UZPLvXkUk-S9YdkvYujPz4fGcsG3ffgl9UIXO2BN1_j-38v1jcPd1Mn_gFOXYsX</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755406120</pqid></control><display><type>article</type><title>WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Oji, Yusuke ; Oka, Yoshihiro ; Nishida, Sumiyuki ; Tsuboi, Akihiro ; Kawakami, Manabu ; Shirakata, Toshiaki ; Takahashi, Kazuko ; Murao, Ayako ; Nakajima, Hiroko ; Narita, Miwako ; Takahashi, Masuhiro ; Morita, Satoshi ; Sakamoto, Junichi ; Tanaka, Toshio ; Kawase, Ichiro ; Hosen, Naoki ; Sugiyama, Haruo</creator><creatorcontrib>Oji, Yusuke ; Oka, Yoshihiro ; Nishida, Sumiyuki ; Tsuboi, Akihiro ; Kawakami, Manabu ; Shirakata, Toshiaki ; Takahashi, Kazuko ; Murao, Ayako ; Nakajima, Hiroko ; Narita, Miwako ; Takahashi, Masuhiro ; Morita, Satoshi ; Sakamoto, Junichi ; Tanaka, Toshio ; Kawase, Ichiro ; Hosen, Naoki ; Sugiyama, Haruo</creatorcontrib><description>How to treat CML patients who are resistant to inhibitors of BCR‐ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib‐treated CML in which intradermally administered WT1 peptide vaccine elicited WT1‐specific immune responses and the resultant reduction in the persistent residual disease in co‐administration of Imatinib. BCR‐ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR‐ABL mRNA levels was associated with the increase in frequency of WT1‐specific cytotoxic T lymphocytes, notably effector‐memory type of that, in the patient’s peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure‐oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib.</description><identifier>ISSN: 0902-4441</identifier><identifier>EISSN: 1600-0609</identifier><identifier>DOI: 10.1111/j.1600-0609.2010.01497.x</identifier><identifier>PMID: 20633041</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Aged ; Antineoplastic Agents - therapeutic use ; Benzamides ; Cancer Vaccines - chemistry ; Cancer Vaccines - immunology ; Cancer Vaccines - therapeutic use ; CML ; Combined Modality Therapy ; Drug Resistance, Neoplasm ; Female ; Fusion Proteins, bcr-abl - antagonists & inhibitors ; Humans ; Imatinib ; Imatinib Mesylate ; immunotherapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy ; Neoplasm, Residual ; Piperazines - therapeutic use ; Protein-Tyrosine Kinases - antagonists & inhibitors ; Pyrimidines - therapeutic use ; RNA, Messenger ; T-Lymphocytes, Cytotoxic - immunology ; Vaccines, Subunit - immunology ; Vaccines, Subunit - therapeutic use ; WT1 peptide vaccine ; WT1 Proteins - chemistry ; WT1 Proteins - immunology</subject><ispartof>European journal of haematology, 2010-10, Vol.85 (4), p.358-360</ispartof><rights>2010 John Wiley & Sons A/S</rights><rights>2010 John Wiley & Sons A/S.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4347-60c36d19f1855091c2e9a0c5882b897c9b7c892b8681d9f0c0a335bbea242d373</citedby><cites>FETCH-LOGICAL-c4347-60c36d19f1855091c2e9a0c5882b897c9b7c892b8681d9f0c0a335bbea242d373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1600-0609.2010.01497.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1600-0609.2010.01497.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20633041$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Oji, Yusuke</creatorcontrib><creatorcontrib>Oka, Yoshihiro</creatorcontrib><creatorcontrib>Nishida, Sumiyuki</creatorcontrib><creatorcontrib>Tsuboi, Akihiro</creatorcontrib><creatorcontrib>Kawakami, Manabu</creatorcontrib><creatorcontrib>Shirakata, Toshiaki</creatorcontrib><creatorcontrib>Takahashi, Kazuko</creatorcontrib><creatorcontrib>Murao, Ayako</creatorcontrib><creatorcontrib>Nakajima, Hiroko</creatorcontrib><creatorcontrib>Narita, Miwako</creatorcontrib><creatorcontrib>Takahashi, Masuhiro</creatorcontrib><creatorcontrib>Morita, Satoshi</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Tanaka, Toshio</creatorcontrib><creatorcontrib>Kawase, Ichiro</creatorcontrib><creatorcontrib>Hosen, Naoki</creatorcontrib><creatorcontrib>Sugiyama, Haruo</creatorcontrib><title>WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient</title><title>European journal of haematology</title><addtitle>Eur J Haematol</addtitle><description>How to treat CML patients who are resistant to inhibitors of BCR‐ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib‐treated CML in which intradermally administered WT1 peptide vaccine elicited WT1‐specific immune responses and the resultant reduction in the persistent residual disease in co‐administration of Imatinib. BCR‐ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR‐ABL mRNA levels was associated with the increase in frequency of WT1‐specific cytotoxic T lymphocytes, notably effector‐memory type of that, in the patient’s peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure‐oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib.</description><subject>Aged</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Benzamides</subject><subject>Cancer Vaccines - chemistry</subject><subject>Cancer Vaccines - immunology</subject><subject>Cancer Vaccines - therapeutic use</subject><subject>CML</subject><subject>Combined Modality Therapy</subject><subject>Drug Resistance, Neoplasm</subject><subject>Female</subject><subject>Fusion Proteins, bcr-abl - antagonists & inhibitors</subject><subject>Humans</subject><subject>Imatinib</subject><subject>Imatinib Mesylate</subject><subject>immunotherapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</subject><subject>Neoplasm, Residual</subject><subject>Piperazines - therapeutic use</subject><subject>Protein-Tyrosine Kinases - antagonists & inhibitors</subject><subject>Pyrimidines - therapeutic use</subject><subject>RNA, Messenger</subject><subject>T-Lymphocytes, Cytotoxic - immunology</subject><subject>Vaccines, Subunit - immunology</subject><subject>Vaccines, Subunit - therapeutic use</subject><subject>WT1 peptide vaccine</subject><subject>WT1 Proteins - chemistry</subject><subject>WT1 Proteins - immunology</subject><issn>0902-4441</issn><issn>1600-0609</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkEtO5DAQhi0EopvHFUbesUpTfuThBQvUggHUiE0jlpZjVyS3knQmTqDZzRHmjHOScWhgPd5U6fdXZfkjhDJYsHguNwuWASSQgVpwiCkwqfLF7oDMvy8OyRwU8ERKyWbkJIQNAHDF8mMy45AJAZLNSfWyZrTDbvAO6aux1rdIfetGi4H2GOvgt21MaONb35g6hsG7MTbOBzRhoqlp6X1jhkiUf3__GXo0Azq6fFzRLqbYDmfkqDJ1wPPPekqeb2_Wy7tk9fTzfnm9SqwUMk8ysCJzTFWsSFNQzHJUBmxaFLwsVG5VmdtCxT4rmFMVWDBCpGWJhkvuRC5OycV-b9dvf40YBt34YLGuTYvbMeg8TSVkjEMkiz1p-20IPVa66-P_-nfNQE-S9UZPLvXkUk-S9YdkvYujPz4fGcsG3ffgl9UIXO2BN1_j-38v1jcPd1Mn_gFOXYsX</recordid><startdate>201010</startdate><enddate>201010</enddate><creator>Oji, Yusuke</creator><creator>Oka, Yoshihiro</creator><creator>Nishida, Sumiyuki</creator><creator>Tsuboi, Akihiro</creator><creator>Kawakami, Manabu</creator><creator>Shirakata, Toshiaki</creator><creator>Takahashi, Kazuko</creator><creator>Murao, Ayako</creator><creator>Nakajima, Hiroko</creator><creator>Narita, Miwako</creator><creator>Takahashi, Masuhiro</creator><creator>Morita, Satoshi</creator><creator>Sakamoto, Junichi</creator><creator>Tanaka, Toshio</creator><creator>Kawase, Ichiro</creator><creator>Hosen, Naoki</creator><creator>Sugiyama, Haruo</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201010</creationdate><title>WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient</title><author>Oji, Yusuke ; Oka, Yoshihiro ; Nishida, Sumiyuki ; Tsuboi, Akihiro ; Kawakami, Manabu ; Shirakata, Toshiaki ; Takahashi, Kazuko ; Murao, Ayako ; Nakajima, Hiroko ; Narita, Miwako ; Takahashi, Masuhiro ; Morita, Satoshi ; Sakamoto, Junichi ; Tanaka, Toshio ; Kawase, Ichiro ; Hosen, Naoki ; Sugiyama, Haruo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4347-60c36d19f1855091c2e9a0c5882b897c9b7c892b8681d9f0c0a335bbea242d373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Aged</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Benzamides</topic><topic>Cancer Vaccines - chemistry</topic><topic>Cancer Vaccines - immunology</topic><topic>Cancer Vaccines - therapeutic use</topic><topic>CML</topic><topic>Combined Modality Therapy</topic><topic>Drug Resistance, Neoplasm</topic><topic>Female</topic><topic>Fusion Proteins, bcr-abl - antagonists & inhibitors</topic><topic>Humans</topic><topic>Imatinib</topic><topic>Imatinib Mesylate</topic><topic>immunotherapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy</topic><topic>Neoplasm, Residual</topic><topic>Piperazines - therapeutic use</topic><topic>Protein-Tyrosine Kinases - antagonists & inhibitors</topic><topic>Pyrimidines - therapeutic use</topic><topic>RNA, Messenger</topic><topic>T-Lymphocytes, Cytotoxic - immunology</topic><topic>Vaccines, Subunit - immunology</topic><topic>Vaccines, Subunit - therapeutic use</topic><topic>WT1 peptide vaccine</topic><topic>WT1 Proteins - chemistry</topic><topic>WT1 Proteins - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Oji, Yusuke</creatorcontrib><creatorcontrib>Oka, Yoshihiro</creatorcontrib><creatorcontrib>Nishida, Sumiyuki</creatorcontrib><creatorcontrib>Tsuboi, Akihiro</creatorcontrib><creatorcontrib>Kawakami, Manabu</creatorcontrib><creatorcontrib>Shirakata, Toshiaki</creatorcontrib><creatorcontrib>Takahashi, Kazuko</creatorcontrib><creatorcontrib>Murao, Ayako</creatorcontrib><creatorcontrib>Nakajima, Hiroko</creatorcontrib><creatorcontrib>Narita, Miwako</creatorcontrib><creatorcontrib>Takahashi, Masuhiro</creatorcontrib><creatorcontrib>Morita, Satoshi</creatorcontrib><creatorcontrib>Sakamoto, Junichi</creatorcontrib><creatorcontrib>Tanaka, Toshio</creatorcontrib><creatorcontrib>Kawase, Ichiro</creatorcontrib><creatorcontrib>Hosen, Naoki</creatorcontrib><creatorcontrib>Sugiyama, Haruo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Oji, Yusuke</au><au>Oka, Yoshihiro</au><au>Nishida, Sumiyuki</au><au>Tsuboi, Akihiro</au><au>Kawakami, Manabu</au><au>Shirakata, Toshiaki</au><au>Takahashi, Kazuko</au><au>Murao, Ayako</au><au>Nakajima, Hiroko</au><au>Narita, Miwako</au><au>Takahashi, Masuhiro</au><au>Morita, Satoshi</au><au>Sakamoto, Junichi</au><au>Tanaka, Toshio</au><au>Kawase, Ichiro</au><au>Hosen, Naoki</au><au>Sugiyama, Haruo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient</atitle><jtitle>European journal of haematology</jtitle><addtitle>Eur J Haematol</addtitle><date>2010-10</date><risdate>2010</risdate><volume>85</volume><issue>4</issue><spage>358</spage><epage>360</epage><pages>358-360</pages><issn>0902-4441</issn><eissn>1600-0609</eissn><abstract>How to treat CML patients who are resistant to inhibitors of BCR‐ABL tyrosine kinase such as Imatinib is a very important and urgent issue in clinical hematology. Here, we report a case of Imatinib‐treated CML in which intradermally administered WT1 peptide vaccine elicited WT1‐specific immune responses and the resultant reduction in the persistent residual disease in co‐administration of Imatinib. BCR‐ABL mRNA levels were being maintained under the detection limit for 8 months since week 77 of vaccination. No adverse effects except local erythema at the injection sites were observed. The tetramer assay revealed that the decrease in BCR‐ABL mRNA levels was associated with the increase in frequency of WT1‐specific cytotoxic T lymphocytes, notably effector‐memory type of that, in the patient’s peripheral blood. The case presented here indicates that WT1 peptide vaccine may become a safe and cure‐oriented therapy for CML patients who have residual disease regardless of the treatment with Imatinib.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20633041</pmid><doi>10.1111/j.1600-0609.2010.01497.x</doi><tpages>3</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0902-4441 |
| ispartof | European journal of haematology, 2010-10, Vol.85 (4), p.358-360 |
| issn | 0902-4441 1600-0609 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_755406120 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Aged Antineoplastic Agents - therapeutic use Benzamides Cancer Vaccines - chemistry Cancer Vaccines - immunology Cancer Vaccines - therapeutic use CML Combined Modality Therapy Drug Resistance, Neoplasm Female Fusion Proteins, bcr-abl - antagonists & inhibitors Humans Imatinib Imatinib Mesylate immunotherapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Neoplasm, Residual Piperazines - therapeutic use Protein-Tyrosine Kinases - antagonists & inhibitors Pyrimidines - therapeutic use RNA, Messenger T-Lymphocytes, Cytotoxic - immunology Vaccines, Subunit - immunology Vaccines, Subunit - therapeutic use WT1 peptide vaccine WT1 Proteins - chemistry WT1 Proteins - immunology |
| title | WT1 peptide vaccine induces reduction in minimal residual disease in an Imatinib‐treated CML patient |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T05%3A42%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=WT1%20peptide%20vaccine%20induces%20reduction%20in%20minimal%20residual%20disease%20in%20an%20Imatinib%E2%80%90treated%20CML%20patient&rft.jtitle=European%20journal%20of%20haematology&rft.au=Oji,%20Yusuke&rft.date=2010-10&rft.volume=85&rft.issue=4&rft.spage=358&rft.epage=360&rft.pages=358-360&rft.issn=0902-4441&rft.eissn=1600-0609&rft_id=info:doi/10.1111/j.1600-0609.2010.01497.x&rft_dat=%3Cproquest_cross%3E755406120%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755406120&rft_id=info:pmid/20633041&rfr_iscdi=true |